Immune Checkpoint Inhibitors – Special Topics – Special Topics: Immune Checkpoint Inhibitors (G7)

Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of agents targeting checkpoint blockade continues to transform the treatment paradigm for many oncology indications at an incredible rate. This Special Topics report provides a comprehensive market forecast of current and emerging immune checkpoint inhibitors and analyzes the market trends and dynamics in a range of oncology indications.

QUESTIONS ANSWERED

  • What is the current landscape for approved immune checkpoint inhibitors? What are the trends in each indication?
  • How will emerging immune checkpoint inhibitors be positioned in the market? How will the indication-specific market trends and dynamics evolve?
  • What is the commercial potential of current and emerging immune checkpoint inhibitors by brand, indication, combination type, and geography? How will the market evolve over the 2019-2029 forecast period?

GEOGRAPHIES

United States, EU5, Japan.

EPIDEMIOLOGY

Drug-treated patient populations by brand, indication, combination type, and geography for indications for which immune checkpoint inhibitors are approved or forecast for approval.

FORECAST

10-year, annualized, drug-level sales of immune checkpoint inhibitors through 2029, segmented by indication, combination type, and geography.

KEY DRUGS COVERED

Currently approved agents targeting PD-1, PD-L1, and CTLA-4.

EMERGING THERAPIES

Phase III/PR.

PRODUCT DESCRIPTION

DRG’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the immune checkpoint inhibitor landscape in relevant oncology indications.

Table of contents

  • Immune Checkpoint Inhibitors - Special Topics - Special Topics: Immune Checkpoint Inhibitors (G7)
    • Special Topics Immune Checkpoint Inhibitors, US, EU5, Japan, December 2021

Login to access report